For research use only. Not for therapeutic Use.
KTX-582（Cat No.:I042633）is a novel small molecule inhibitor designed to target specific enzymes involved in the regulation of cellular metabolism and immune response. It has shown promise in preclinical studies for its ability to modulate inflammation and immune cell activation, making it a potential treatment for autoimmune diseases, chronic inflammatory conditions, and certain cancers. KTX-582 works by disrupting signaling pathways that contribute to disease progression. Ongoing research is focused on assessing its safety, efficacy, and pharmacokinetics, with the aim of advancing it as a therapeutic option for various immune-related and inflammatory disorders.
| CAS Number | 2573298-13-0 |
| Synonyms | N-[2-[4-[[3-[3-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]cyclobutyl]oxypropyl-methylamino]methyl]cyclohexyl]-6-(2-hydroxypropan-2-yl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide |
| Molecular Formula | C45H51F3N8O7 |
| Purity | ≥95% |
| IUPAC Name | N-[2-[4-[[3-[3-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]cyclobutyl]oxypropyl-methylamino]methyl]cyclohexyl]-6-(2-hydroxypropan-2-yl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide |
| InChI | InChI=1S/C45H51F3N8O7/c1-44(2,62)31-22-34-26(19-35(31)51-40(58)33-9-5-10-37(50-33)45(46,47)48)24-55(53-34)28-13-11-25(12-14-28)23-54(3)17-6-18-63-29-20-27(21-29)49-32-8-4-7-30-39(32)43(61)56(42(30)60)36-15-16-38(57)52-41(36)59/h4-5,7-10,19,22,24-25,27-29,36,49,62H,6,11-18,20-21,23H2,1-3H3,(H,51,58)(H,52,57,59) |
| InChIKey | CKFOAVDINFHZIR-UHFFFAOYSA-N |
| SMILES | CC(C)(C1=CC2=NN(C=C2C=C1NC(=O)C3=NC(=CC=C3)C(F)(F)F)C4CCC(CC4)CN(C)CCCOC5CC(C5)NC6=CC=CC7=C6C(=O)N(C7=O)C8CCC(=O)NC8=O)O |
